<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820441</url>
  </required_header>
  <id_info>
    <org_study_id>38RC15.175</org_study_id>
    <nct_id>NCT02820441</nct_id>
  </id_info>
  <brief_title>Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance</brief_title>
  <acronym>ZODIAC</acronym>
  <official_title>Adaptative Servoventilation Compliance in Left Ventricular Dysfunction Patients With Central Sleep Apnea: Benefit of One Month Hypnotic (Zopiclone) Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluate the effect of adaptative servoventilation (ASV) initiation combined with
      14 days Zopiclone vs Placebo treatment in patients with central sleep apnea (CSA) syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ASV remain the optimal treatment for CSA in Heart Failure patients with preserved left
      ventricular ejection fraction (LVEF).

      Yet, the adaptation to the ventilation is extremely challenging and the resulting
      difficulties encountered to sleep induction might be a reason for dropping out.

      Zopiclone is indicated for the short-term treatment of insomnia where sleep initiation or
      sleep maintenance are prominent symptoms. In this study, Zopiclone, as sedative and hypnotic
      agent, is used during the ASV initiation period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average use of the Adapative Servo Ventilation device per day assessed by the device data</measure>
    <time_frame>one month</time_frame>
    <description>daily use of the device (hours/day, mean value), amount of hours and number of day the device has been used as assessed by the device data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average use of the Adapative Servo Ventilation device per day assessed by the device data</measure>
    <time_frame>3 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Apnea, Hypopnea Index (number/hour)</measure>
    <time_frame>12 months</time_frame>
    <description>Index assessed by device data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime sleepiness assessed by the Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime sleepiness assessed by the Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime sleepiness assessed by the Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthenia assessed by Pichot scale</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthenia assessed by Pichot scale</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthenia assessed by Pichot scale</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in New York Heart Association score</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in New York Heart Association score</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in New York Heart Association score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of prescription of hypnotics drug</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Sleep Apnea, Central</condition>
  <condition>Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>ZOPICLONE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zopiclone 3.5 mg capsule by mouth daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 3.5 mg capsule by mouth daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zopiclone</intervention_name>
    <arm_group_label>ZOPICLONE</arm_group_label>
    <other_name>IMOVANE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged between 18 and 90 years at the initial visit

          -  Central Sleep Apnea with an AHI ≥ 15/h and at least 50% of central events indicating
             an ASV therapy, as determined by a ventilatory polygraphy (PG) or a polysomnography
             (PSG)

          -  Cardiac Dysfunction with Left Ventricular Ejection fraction(LVEF)&gt; 45% determined by a
             transthoracic echocardiography (TTE), known for more than 12 weeks and stable for at
             least 4 weeks;

          -  Compliance less than 3 hours after 7 days of the setting up of ASV;

          -  Patient affiliated to a social security scheme or being beneficiary of such scheme;

          -  Patient voluntarily participating in the research, with written informed consent

        Exclusion Criteria:

          -  Current use of continuous positive airway pressure (cPAP) for treatment of sleep apnea
             during the last 12 months

          -  Presence of chronic symptomatic heart failure with reduced left ventricular ejection
             fraction (LVEF ≤ 45%), and a CSA moderate to severe (AHI ≥15 / h)

          -  Presence of severe pulmonary bullous disease

          -  Presence of Pneumothorax or pneumomediastinum

          -  Hypotension, especially if associated with depletion of intravascular volume

          -  Dehydration

          -  Leaking of cerebrospinal fluid, cranial surgery or trauma recently.

          -  Episode of acute respiratory failure or heart failure in the previous month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie DESTORS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble Alpes, FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie DESTORS, MD</last_name>
    <phone>+33 (0)476 769 265</phone>
    <email>mdestors@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andry RAKOTOVAO, PhD</last_name>
    <phone>+33 (0)476 766 148</phone>
    <email>arakotovao@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique de Physiologie Sommeil et Exercice, Pole Thorax et Vaisseaux , University Hospital Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie DESTORS, MD, BSc</last_name>
      <phone>+33 (0)476 769 265</phone>
      <email>mdestors@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Andry RAKOTOVAO, PhD</last_name>
      <phone>+33 (0)476 766 148</phone>
      <email>arakotovao@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Renaud TAMISIER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Boccon-Gibod I, Bouillet L. [Angioedema and urticaria]. Ann Dermatol Venereol. 2014 Nov;141 Suppl 3:S586-95. doi: 10.1016/S0151-9638(14)70162-0. Review. French.</citation>
    <PMID>25539680</PMID>
  </reference>
  <reference>
    <citation>Pagnier A. [Hereditary angioedema in childhood. Diagnosis and therapeutic challenges]. Presse Med. 2015 Jan;44(1):89-95. doi: 10.1016/j.lpm.2014.07.018. Epub 2014 Dec 12. Review. French.</citation>
    <PMID>25511651</PMID>
  </reference>
  <reference>
    <citation>Dinkel HP, Maroske J, Schrod L. Sonographic appearances of the abdominal manifestations of hereditary angioedema. Pediatr Radiol. 2001 Apr;31(4):296-8.</citation>
    <PMID>11321752</PMID>
  </reference>
  <reference>
    <citation>Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol. 2009 Nov;161(5):1153-8. doi: 10.1111/j.1365-2133.2009.09366.x. Epub 2009 Jun 22.</citation>
    <PMID>19709101</PMID>
  </reference>
  <reference>
    <citation>Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):18. doi: 10.1186/1710-1492-6-18.</citation>
    <PMID>20667121</PMID>
  </reference>
  <reference>
    <citation>El-Hachem C, Amiour M, Guillot M, Laurent J. [Hereditary angioneurotic edema: a case report in a 3-year-old child]. Arch Pediatr. 2005 Aug;12(8):1232-6. French.</citation>
    <PMID>15890504</PMID>
  </reference>
  <reference>
    <citation>Farkas H. Management of upper airway edema caused by hereditary angioedema. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):19. doi: 10.1186/1710-1492-6-19.</citation>
    <PMID>20667122</PMID>
  </reference>
  <reference>
    <citation>Sanchez A, Ecochard A, Maestracci M, Rodiere M. [Hereditary angioedema causing colocolic intussusception]. Arch Pediatr. 2008 Mar;15(3):271-4. doi: 10.1016/j.arcped.2007.12.004. Epub 2008 Mar 10. French.</citation>
    <PMID>18329867</PMID>
  </reference>
  <reference>
    <citation>Pritzker HA, Levin TL, Weinberg G. Recurrent colocolic intussusception in a child with hereditary angioneurotic edema: reduction by air enema. J Pediatr Surg. 2004 Jul;39(7):1144-6.</citation>
    <PMID>15213920</PMID>
  </reference>
  <reference>
    <citation>Parisi G, Chiarelli A, Squadrone NP, Galante E. Hereditary angioedema, a rare cause of recurrent abdominal pain. A report of 2 clinical cases and comments of a general nature Allergy Asthma Proc. 2013 Jul-Aug;34(4):312-27</citation>
  </reference>
  <reference>
    <citation>MacGinnitie AJ. Pediatric hereditary angioedema. Pediatr Allergy Immunol. 2014 Aug;25(5):420-7. doi: 10.1111/pai.12168. Epub 2013 Dec 9. Review.</citation>
    <PMID>24313851</PMID>
  </reference>
  <reference>
    <citation>Deroux A, Vilgrain I, Dumestre-Pérard C, Boccon-Gibod I, Bouillet L. Towards a specific marker for acute bradykinin-mediated angioedema attacks: a literature review. Eur J Dermatol. 2015 Jul-Aug;25(4):290-5. doi: 10.1684/ejd.2015.2547. Review.</citation>
    <PMID>25905454</PMID>
  </reference>
  <reference>
    <citation>Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002 Aug 22;347(8):621-2.</citation>
    <PMID>12192030</PMID>
  </reference>
  <reference>
    <citation>Cugno M, Zanichelli A, Bellatorre AG, Griffini S, Cicardi M. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy. 2009 Feb;64(2):254-7. doi: 10.1111/j.1398-9995.2008.01859.x. Epub 2008 Dec 4.</citation>
    <PMID>19076541</PMID>
  </reference>
  <reference>
    <citation>Hogan AD, Schwartz LB. Markers of mast cell degranulation. Methods. 1997 Sep;13(1):43-52.</citation>
    <PMID>9281467</PMID>
  </reference>
  <reference>
    <citation>Brickman CM, Frank MM, Kaliner M. Urine-histamine levels in patients with hereditary angioedema (HAE). J Allergy Clin Immunol. 1988 Sep;82(3 Pt 1):403-6.</citation>
    <PMID>3170987</PMID>
  </reference>
  <reference>
    <citation>Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia. 2004 Jul;59(7):695-703. Review.</citation>
    <PMID>15200544</PMID>
  </reference>
  <reference>
    <citation>Kasperska-Zając A, Grzanka A, Czecior E, Misiolek M, Rogala B, Machura E. Acute phase inflammatory markers in patients with non-steroidal anti-inflammatory drugs (NSAIDs)-induced acute urticaria/angioedema and after aspirin challenge. J Eur Acad Dermatol Venereol. 2013 Aug;27(8):1048-52. doi: 10.1111/j.1468-3083.2012.04486.x. Epub 2012 Feb 21.</citation>
    <PMID>22348297</PMID>
  </reference>
  <reference>
    <citation>Fujii K, Konishi K, Kanno Y, Ohgou N. Acute urticaria with elevated circulating interleukin-6 is resistant to anti-histamine treatment. J Dermatol. 2001 May;28(5):248-50.</citation>
    <PMID>11436361</PMID>
  </reference>
  <reference>
    <citation>Kasperska-Zajac A, Brzoza Z. Increased D-dimer concentration in plasma of patients with severe acute urticaria. Br J Dermatol. 2009 Dec;161(6):1409-10. doi: 10.1111/j.1365-2133.2009.09466.x. Epub 2009 Sep 15.</citation>
    <PMID>19754863</PMID>
  </reference>
  <reference>
    <citation>Brevet: w/o 2008 062314 circulating ve-cadherin as a predictive marker of sensitivity or resistance to anti-tumoral treatment, and improved method for the detection of soluble proteins.</citation>
  </reference>
  <reference>
    <citation>Bouillet L, Sidibé A, Polena H, Mannic T, Deroux A, Stidder B, Vittecoq O, Vilgrain I. [Endothelial junctions: exploiting their instability in the development of biomarkers for vascular remodelling]. Med Sci (Paris). 2014 Jun-Jul;30(6-7):633-5. doi: 10.1051/medsci/20143006012. Epub 2014 Jul 11. French.</citation>
    <PMID>25014453</PMID>
  </reference>
  <reference>
    <citation>Bouillet L, Vilgrain I. VE-cadherin, a potential marker for endothelial cell activation during hereditary angioedema attacks. J Allergy Clin Immunol. 2014 Jul;134(1):241. doi: 10.1016/j.jaci.2014.04.016. Epub 2014 May 27.</citation>
    <PMID>24875615</PMID>
  </reference>
  <reference>
    <citation>Sidibé A, Polena H, Pernet-Gallay K, Razanajatovo J, Mannic T, Chaumontel N, Bama S, Maréchal I, Huber P, Gulino-Debrac D, Bouillet L, Vilgrain I. VE-cadherin Y685F knock-in mouse is sensitive to vascular permeability in recurrent angiogenic organs. Am J Physiol Heart Circ Physiol. 2014 Aug 1;307(3):H455-63. doi: 10.1152/ajpheart.00774.2013. Epub 2014 May 23.</citation>
    <PMID>24858856</PMID>
  </reference>
  <reference>
    <citation>Sidibé A, Polena H, Razanajatovo J, Mannic T, Chaumontel N, Bama S, Maréchal I, Huber P, Gulino-Debrac D, Bouillet L, Vilgrain I. Dynamic phosphorylation of VE-cadherin Y685 throughout mouse estrous cycle in ovary and uterus. Am J Physiol Heart Circ Physiol. 2014 Aug 1;307(3):H448-54. doi: 10.1152/ajpheart.00773.2013. Epub 2014 May 23.</citation>
    <PMID>24858855</PMID>
  </reference>
  <reference>
    <citation>Bouillet L, Mannic T, Arboleas M, Subileau M, Massot C, Drouet C, Huber P, Vilgrain I. Hereditary angioedema: key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and edema formation. J Allergy Clin Immunol. 2011 Jul;128(1):232-4. doi: 10.1016/j.jaci.2011.02.017. Epub 2011 Mar 24.</citation>
    <PMID>21439626</PMID>
  </reference>
  <reference>
    <citation>Suffritti C, Zanichelli A, Maggioni L, Bonanni E, Cugno M, Cicardi M. High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency. Clin Exp Allergy. 2014 Dec;44(12):1503-14. doi: 10.1111/cea.12293.</citation>
    <PMID>24552232</PMID>
  </reference>
  <reference>
    <citation>Kahn R, Herwald H, Müller-Esterl W, Schmitt R, Sjögren AC, Truedsson L, Karpman D. Contact-system activation in children with vasculitis. Lancet. 2002 Aug 17;360(9332):535-41.</citation>
    <PMID>12241658</PMID>
  </reference>
  <reference>
    <citation>Ghannam A, Sellier P, Defendi F, Favier B, Charignon D, López-Lera A, López-Trascasa M, Ponard D, Drouet C. C1 inhibitor function using contact-phase proteases as target: evaluation of an innovative assay. Allergy. 2015 Sep;70(9):1103-11. doi: 10.1111/all.12657. Epub 2015 Jun 9.</citation>
    <PMID>26010015</PMID>
  </reference>
  <reference>
    <citation>Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009 Mar 26;113(13):2878-87. doi: 10.1182/blood-2008-06-165845. Epub 2008 Nov 13. Review.</citation>
    <PMID>19008457</PMID>
  </reference>
  <reference>
    <citation>Blohmé G. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med Scand. 1972 Oct;192(4):293-8.</citation>
    <PMID>4562897</PMID>
  </reference>
  <reference>
    <citation>Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension. 1999 Jun;33(6):1431-5.</citation>
    <PMID>10373228</PMID>
  </reference>
  <reference>
    <citation>Cugno M, Hack CE, de Boer JP, Eerenberg AJ, Agostoni A, Cicardi M. Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med. 1993 Jan;121(1):38-43.</citation>
    <PMID>8426080</PMID>
  </reference>
  <reference>
    <citation>Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med. 1972 Apr 13;286(15):808-12.</citation>
    <PMID>4551861</PMID>
  </reference>
  <reference>
    <citation>Joseph K, Tholanikunnel BG, Wolf B, Bork K, Kaplan AP. Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. J Allergy Clin Immunol. 2016 Jun;137(6):1822-1829.e1. doi: 10.1016/j.jaci.2015.07.041. Epub 2015 Sep 26.</citation>
    <PMID>26395818</PMID>
  </reference>
  <reference>
    <citation>Kaplan AP, Austen KF. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med. 1971 Apr 1;133(4):696-712.</citation>
    <PMID>4251126</PMID>
  </reference>
  <reference>
    <citation>Kleniewski J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med. 1992 Jul;120(1):129-39.</citation>
    <PMID>1535355</PMID>
  </reference>
  <reference>
    <citation>Kluft C, Trumpi-Kalshoven MM, Jie AF, Veldhuyzen-Stolk EC. Factor XII-dependent fibrinolysis: a double function of plasma kallikrein and the occurrence of a previously undescribed factor XII- and kallikrein-dependent plasminogen proactivator. Thromb Haemost. 1979 Jun 30;41(4):756-73.</citation>
    <PMID>483248</PMID>
  </reference>
  <reference>
    <citation>Nielsen EW, Johansen HT, Høgåsen K, Wuillemin W, Hack CE, Mollnes TE. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol. 1996 Aug;44(2):185-92.</citation>
    <PMID>8711433</PMID>
  </reference>
  <reference>
    <citation>Reshef A, Zanichelli A, Longhurst H, Relan A, Hack CE. Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy. 2015 May;70(5):506-13. doi: 10.1111/all.12587. Epub 2015 Feb 23.</citation>
    <PMID>25640891</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Sleep Apnea, Central</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zopiclone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

